{"name":"Vanda Pharmaceuticals","slug":"vanda-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Milsaperidone","genericName":"Milsaperidone","slug":"milsaperidone","indication":"Other","status":"marketed"},{"name":"Iloperidone and VHX-896","genericName":"Iloperidone and VHX-896","slug":"iloperidone-and-vhx-896","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Milsaperidone","genericName":"Milsaperidone","slug":"milsaperidone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Iloperidone and VHX-896","genericName":"Iloperidone and VHX-896","slug":"iloperidone-and-vhx-896","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBfellnbGJVYlhMRU44NVlCSEJCVmFOYUllVU41Sm1DTHFqZWV1YmFZNVRYMWpEUjJxZzlCTUU5R0xRNENHN2tPUHBTazNhN2RUOEEzMTFteUlaOXpFa2M4NXp4bjhNcmpKdXMxS01B?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Vanda Pharma (VNDA) - Stock Titan","headline":"If You Invested $1,000 in Vanda Pharma (VNDA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxPRnVwWVR4S1RRN1RSczZsa2szWUl3YXFhLVNlM0NJU2NVR0V0MkxUOTRqSjZvR19BNTZLeUxPVnBSRU1keE5ieU12UVRnaEdWTGcwdFpyZ1ZKZktxTmZkZWUyb0Iza2Fuamo3bVhyRlNrLVFnOGNlNV9XNHFjOG5nQXh2QUxQUFFOSm90a1pnODAwMjhlVFptc3pFazNzQ3dJOXJEcWxSdDRBVGxadl8yUnpwczJacGFhUEc5MUUtODRDWkFQWl8zUlBfU3EtaWlxdGRhdXYyUGQ5VHZWX3VFeEZKN0piWkFTTUFDVHJuZkNzNzFEWmljQWRSZ0tVWFpuRlJR?oc=5","date":"2026-03-19","type":"regulatory","source":"PR Newswire","summary":"Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods - PR Newswire","headline":"Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOeHJwUVpQWHItdzlVMDhUMzVobThYMmJ4VGJVcm91cjg4RmZlX1g4UkJNSUUwSTQ2QmhOQXdDYVRpTEhpNURzT3VOZFFkTXdSN1RjQmxmdUtNZzhwSWhYYUY5UXRuRy1PNk41ajNoRjlONXI0N1dMT2x4RFBwcno3amsyeVRXVmpSMFo5NGdZczgydmFUV0szSjkyNTdGdTNXOG9sT3ZkaGdvVWJzWHdpTTk3dWFkOFJtQnhOelhEN1dkLTJBeGx0aWJSU1E0SHJXLU5YN2c0RmtVS1FPeG9RZA?oc=5","date":"2026-02-26","type":"pipeline","source":"PR Newswire","summary":"Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - PR Newswire","headline":"Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQTUJLRnFCbF8tS1ZPZHc5Qk4tblVpaWR2eVZ0ZTdfSE1MamQwVXpXZVRFS3ZHMUVSbkhIOURueFAxb3U4WkhPS0NIb2U4TWxYLVFVTnd2NkJ6bVlwSUZWdlM3a2ZRbm9VY1RFMm9WREMtMUtZc2w2YkZzVVBsZHZoNDVCSUJ1alBpbGxaRDZJSW1EdUdqVjY3bQ?oc=5","date":"2026-02-23","type":"regulatory","source":"fiercepharma.com","summary":"Vanda, with FDA nod for Bysanti, gains 2nd new drug approval in as many months - fiercepharma.com","headline":"Vanda, with FDA nod for Bysanti, gains 2nd new drug approval in as many months","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-20","type":"regulatory","source":"PR Newswire","summary":"Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovatio","headline":"Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Sch","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQSDlmRFdmTXVsdGgyTWk4R01jMWxySU1tajlubU1ETVIyVEFVejlIS3pZLWtXNHJRVHd3T3lQbDZiV1RlZFFIdVF2Tk5sTkhRSUdqSU16VUZTcHM4bWV3V3MzQzR6RFMydzg4SGVtZVRLVEpaTGc4WnJRWWRJRmc5bXlBeFBINE16TDBnODU4WlR0aUlVY0tWLW9kZ2FSa1IwQUF5VnduS2JMcnJNbEE1S2xB?oc=5","date":"2026-02-20","type":"trial","source":"Stock Titan","summary":"New bipolar and schizophrenia drug builds on 100,000 patient-years of data - Stock Titan","headline":"New bipolar and schizophrenia drug builds on 100,000 patient-years of data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOUWoyU2JYVGI4OGFFdDJJNDNzalE5bjFzTktsUWtadDZqS19xV2Y3WlBVRjFXRkpNVVJBdmFCWkpPMG9RcXQzOG56b2Z0TUxZNFZ2dllnbndBS254VGRTVkQ3NzNEdlc0bnNHSk9fUnFZUTR3MmdYcjg1TVBXNUY3clZ6NE5VUFZ1SXlFNFZhc1hvZndCTmVxdjRwdFpZZVh0UG1MaEdCcEloVkItQi1yOXQ3OHhzb2R4NFRKU3NUR1VFRDdpQlRMYklnTGFrUGFQQW53?oc=5","date":"2026-02-11","type":"earnings","source":"PR Newswire","summary":"Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire","headline":"Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPTlFoUnV3MjJxM2xwTngzeTVtOExTbHlEVlZCVFoxM2ZsYTRpaW9RTFYyaE1pWGJFWEhGYmhpbHFfQjgtS3d5ZU56WTdaTXFpWW53M2hjWGJWeHEyZVdGUVpPOW1XLTRQZkVINW9LU0VpSDlHQWZWYW50U0VkMHI5NVJjenc0OXkxVjctc3RfSVBtVTQ2LUE?oc=5","date":"2026-02-04","type":"earnings","source":"Yahoo Finance","summary":"Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - Yahoo Finance","headline":"Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOajZnaGxIcTJFeEJtQ1Q2Vm1lRmhFRG5tZ3ZRelJoOHNmUE1jcW9TTE5PRGFyVFJyN2Z4VXBmTTVBY3JxQ3hxS3NjbUttbmVCcGRPV0lEMS05N3psdVJXVkozQjhtSWl4aXdBeW0wV2R4eTJSZGFCZFE3dVQ2VllKUDFrd2RwUENNeUhmaXJoMkJTakNjT2xXMVBlTk5HTXRHZFVGb0xxQm9XZjVOaUVF?oc=5","date":"2026-01-02","type":"regulatory","source":"fiercepharma.com","summary":"Vanda's motion sickness drug, Agios' thalassemia treatment make the grade with FDA - fiercepharma.com","headline":"Vanda's motion sickness drug, Agios' thalassemia treatment make the grade with FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOMnM0QjRKNEFIMmNpYnNkSlFxNjlURUJxSjdQT3NDRi02UEJpSjlwZTgtR25JUWdyeEZnQzY4Q0xxenIwN2s5LXhETmhETVRuMl9Damk2dDJDdlB2QkY2dHVmOXJjU3BtcDBfeXY1cU5Nck1GQzdtNnY2NG1EdFRfb2FUSUtMZFVjUkhwUlFmX1ltWTlSNVlRUThKTkVnNTZRc003S0QzOGtta0x6Zm9VQmIwTDJsc3JCd3hNbFEtYWp0anJicDlDRU13?oc=5","date":"2025-12-31","type":"regulatory","source":"Reuters","summary":"US FDA approves Vanda Pharmaceuticals' motion sickness drug - Reuters","headline":"US FDA approves Vanda Pharmaceuticals' motion sickness drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOMmcwZVRnSXZuRXR6azJzWWpVbTF4Z1dyRHBjS2llUnY1SmFTRzVCc0ZHelRVXzg4TWpQcEFfT25HSUxmSFhuU3YyLXlmVy0wX21jbG90ai0xUFYycjJGYUNuVzgtWHduV3lIOXJZbW01cF9IQWRyN1FmLVJ1R3owU01VZnpCSU54R1JpY3IycnpLTUx6eUdiRVhOemxmbXR2U0pvWm5Ld0R2cVNvWFhr?oc=5","date":"2025-12-31","type":"regulatory","source":"Pharmaceutical Technology","summary":"FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus - Pharmaceutical Technology","headline":"FDA approves Vanda Pharmaceuticals’ motion sickness drug Nereus","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPcmQxVmZLR0JCcjlPNDlxNkNMRC1hWHlKUDZaZzdQclJ1YmF2ck8zd2lxTXd6VWgzMmlQb1otMHNQRU1sT1pJcGFEMkVuX1psUjNaNm9OM3VHTTV5cllhdjR4TmxoejF3NjdNTUgtaEVtNmV6LVZRRUlfNDdBUTI3dS1PZ3pXa3dnTFQtWHpQZTA1dmw3UmpraEtOQzVRVlEtNDhJNnV2c3JUOEFWWmxnY0FuSjdvRjdUNE8za0hqSm96cnI3cDMyNDN6ZHFmLWJZV1ZvOUN3?oc=5","date":"2025-11-28","type":"regulatory","source":"PR Newswire","summary":"Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - PR Newswire","headline":"Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}